BrainFutures

BrainFutures and University of California, Berkeley's Collaborative for the Economics of Psychedelics (CEP) are proud to announce the release of our groundbreaking whitepaper: "Scaling Psychedelic Therapies in the Health System." Our survey of mental health #providers across 15 states reveals significant interest in adopting psychedelic therapies alongside challenges.?To tackle some of these challenges, we are #convening providers from across the country on April 1st, 2025 (link to register in the comments). Key Findings Include: ?? Strong Interest in Psychedelic Therapy Expansion: Two-thirds plan to expand psychedelic therapy services, and half expect to offer new psychedelic treatments within six months of FDA approval. ?? Cash-Pay Dominance: Most providers rely on cash-pay models for psychedelic therapy, with little expectation of insurance coverage. This raises concerns about #access and equity, given the expected high out-of-pocket costs of psychedelic therapy. ?? Mission-Driven, Not Profit-Driven: Providers cite a commitment to #patient care as the primary motivator for offering psychedelic therapies rather than financial incentives. Read the full report now to learn more: https://lnkd.in/e7EPqKU6 #psychedelictherapy #healthcare #mentalhealth #healthsystem #psychedelics #access #psychedelicmedicine? Sarah Norman Jazz Glastra Brandon Truax, MS, MBA Elliot Marseille Owen M.

BrainFutures and the University of California, Berkeley's Collaborative for the Economics of Psychedelics (CEP) recently released "Scaling Psychedelic Therapies in the Health System." This publication explores providers' interest and readiness in expanding psychedelic therapies by surveying 20 providers about their views on the barriers and opportunities in implementing these treatments once they receive FDA approval. Swipe through below to explore key findings from the paper and dive in below for the full exploration: https://lnkd.in/e7EPqKU6 #healthcare #healthsystem #psychedelictherapy #psychedelics?

Building on the success and momentum of past meetings, #RAMHT is excited to announce our next event for?May 18th in #LosAngeles?– coinciding with the American Psychiatric Association (#APA)?annual meeting! ? Led by?Owen M.?and?Carlene MacMillan, MD, FCTMSS,DFAACAP, of?#TheFrontierPsychiatrists, as well as?Grady Hannah, Co-Founder of?NightWare, the?RAMHT LA 2025?program will feature leading industry voices and panel discussions focused on: - Brain Stimulation: New Catalysts Accelerating Broad Adoption, moderated by?Chris Aiken, MD,?Editor in Chief of?The Carlat Psychiatry Report?and Assistant Professor, NYU School of Medicine. - Preparing for the Integration of Psychedelics in Patient Care, moderated by?Sarah Norman, Executive Director,?BrainFutures. Please join us for an engaging evening of dialogue focused on how rapid-acting mental health treatments are changing the landscape of psychiatric practice and care. ? Tickets can be purchased via Eventbrite at?bit.ly/3DQAudx?and more information can be found on the RAMHT website at?bit.ly/4hgNln8LI. ? #mentalhealth #patientaccess #brainstimulation #psychiatry #clinicalpractice #psychedelictherapy #patientcare

Save the date! BrainFutures is excited to invite you to a Virtual Provider Roundtable on April 1st at 12 PM EST / 9 AM PST. Register now to join us next week! Register here: https://lnkd.in/e-uZFrmp This session is a follow-up to BrainFutures and the Collaborative of the Economics for Psychedelics’ new whitepaper, Scaling Psychedelics in the Health System. This roundtable will dive into the real-world practicalities of integrating psychedelic therapies into healthcare settings. What to Expect: ?? A provider-led discussion exploring the insights and recommendations from the whitepaper ?? Key takeaways on the challenges and opportunities providers will face once psychedelic therapies are FDA-approved ?? A moderated conversation featuring: Dr. Kwasi Adusei, DNP, Dr. Elliot Marseille, DrPH, MPP, Dr. Sandhya Prashad, MD, and Dr. Brian Richards, MD. The session will be moderated by BrainFutures’ Executive Director, Sarah Norman, offering an in-depth look into the current landscape and future possibilities of psychedelic therapies in healthcare. #PsychedelicTherapies #MentalHealthCare #HealthInnovation #PsychedelicScience #ProviderRoundtable #HealthcareProfessionals #BrainFutures #Economics #PsychedelicsInHealthcare

Save the Date! BrainFutures is excited to invite you to a Virtual Provider Roundtable on April 1st at 12 PM EST / 9 AM PST. Register now to join the conversation! Register here: https://lnkd.in/eKCENha9 This session is a follow-up to BrainFutures and the Collaborative of the Economics for Psychedelics’ new whitepaper, Scaling Psychedelics in the Health System. This roundtable will dive into the real-world practicalities of integrating psychedelic therapies into healthcare settings. What to Expect: ?? A provider-led discussion exploring the insights and recommendations from the whitepaper ?? Key takeaways on the challenges and opportunities providers will face once psychedelic therapies are FDA-approved ?? A moderated conversation featuring: Dr. Kwasi Adusei, DNP, Dr. Elliot Marseille, DrPH, MPP, Dr. Sandhya Prashad, MD, and Dr. Brian Richards, MD. The session will be moderated by BrainFutures’ Executive Director, Sarah Norman, offering an in-depth look into the current landscape and future possibilities of psychedelic therapies in healthcare. #PsychedelicTherapies #MentalHealthCare #HealthInnovation #PsychedelicScience #ProviderRoundtable #HealthcareProfessionals #BrainFutures #Economics #PsychedelicsInHealthcare

Grateful for this team and the milestones they've achieved in bringing this crucial programming to youth across Howard County, MD.

Team sports have been shown to improve executive function in children, leading to better outcomes in school grades, improved memory, emotional resilience, and many other positive developmentally related qualities. As part of BrainFutures’ commitment to advancing positively impactful executive function programming for youth, we are encouraged by new studies, like the one below, conducted in The Netherlands at the University Medical Center Groningen. https://lnkd.in/ghSPYdWf

GH Research plc recently published the results of its phase 2b clinical trial of GH001, an inhalable mebutoenin product, which demonstrated rapid and significant improvements in treatment-resistant depression symptoms. Patients who received GH001 experienced a 57.7% remission rate, compared to 0% in the placebo group. At BrainFutures, we’re always encouraged by novel approaches to breakthrough treatments. We are optimistic that new treatments like this can help expand equitable and comprehensive access to quality healthcare interventions for the people who need them most. Find out more at the link below ?? https://lnkd.in/ebkrSAJG

As Black History Month is well underway, BrainFutures would like to celebrate the incredible achievements of Black American trailblazers in mental health and their pivotal contributions to the field. Swipe below to discover inspiring stories of excellence from leading researchers and clinicians. For more information, check out Mental Health America's extensive list of profiles highlighting Black pioneers in mental health and other resources available here: https://lnkd.in/dPDdCfR

We're grateful to feature Dr. Bruce E. Wexler, MD in an in-depth exploration of executive function, how this can inform lifestyles and behaviors, and how the ACTIVATE? program creates unique infrastructure for growth and stability. Dive into the Q&A below ?? #youth #newresearch #executivefunction #mentalhealth